


# THE DANGERS OF DELAYED ACCESS TO CLINICAL TRIAL DATA

## DELAYED CLINICAL DATA DELIVERY IS A GROWING PROBLEM




**62%** of respondents do not get all of their data in real-time.

The issue is particularly pressing with biomarker data, **13%** of which may not be available until the trial has ended, eliminating its value in developing and delivering precision medicine.



## WITHOUT TIMELY ACCESS TO DATA, SERIOUS ISSUES GO UNDETECTED



## TOP ISSUES EXPERIENCED IN ACCESSING REAL-TIME CLINICAL TRIAL DATA



Data entry delays



Cleaning backlog



Complex edit checks



Inconsistent data formats



Meta data for different sources



Latency issues with the system




Missing data



Inaccurate data

## HOW LONG DOES IT TAKE TO RECEIVE CLINICAL TRIAL DATA FROM INTERNAL AND EXTERNAL PARTNERS, ONCE IT HAS BEEN REQUESTED?



## REAL-TIME ACCESS TO CLINICAL TRIAL DATA CAN REVOLUTIONIZE YOUR CLINICAL TRIALS



Improved data quality



Informed decision-making



Reduce trial timelines and cost



Secure patient safety

Visit [remarque.com](https://remarque.com) to learn how we can help you optimize your clinical trial data, maximize return and minimize risk.

READ MORE: IS A LACK OF REAL-TIME DATA HOLDING TRIALS BACK?

<https://pharmaphorum.com/r-d/is-a-lack-of-real-time-data-holding-trials-back>

**SOURCE:**

- <sup>1</sup>Challenges And Opportunities In Clinical Data Management RESEARCH REPORT 2018 by: Pharma Intelligence
- <sup>2</sup>Ibid.
- <sup>3</sup>Ibid.
- <sup>4</sup>Ibid.